Drug Trial Radar · NCT05220072
Mass Balance Recovery and Metabolite Identification of Carbon-14 BIA 28-6156
Last checked: Nov 20, 2026Latest source record: May 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6
Actual
Start
Aug 28, 2021
Primary completion
Oct 16, 2021
Study completion Oct 16, 2021
Sponsor
- Lead sponsor
- Bial R&D Investments, S.A.Industry
- Sponsor type
- Industry
- First posted
- Feb 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 30 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study is designed to determine the absorption, distribution, metabolism and elimination (ADME) of BIA 28-6156 in humans, further explore the PK of BIA 28-6156, evaluate the extent of distribution of total radioactivity into blood cells, provide additional safety and tolerability information and collect samples for metabolite profiling and structural identification.
Conditions
- Parkinson Disease
Interventions
Carbon-14 BIA 28-6156Drug
Carbon-14 BIA 28-6156 60 mg, containing NMT 3.7 MBq Carbon-14
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mass balance recovery of total radioactivity in all excreta (urine and faeces)Time frame: Urine: Day 1 through Day 11, Faeces: Day -1 through Day 11
- Collection of urine and faecal samples for total radioactivityTime frame: Urine and Faeces: Pre-dose until 288 hours post-dose
- Collection of plasma samples for metabolite profilingTime frame: Pre-dose until 240 hours post-dose
- Collection of plasma samples for structural identificationTime frame: Pre-dose until 240 hours post-dose
- Collection of whole blood samples for total radioactivityTime frame: Pre-dose until 240 hours post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Quotient Sciences
Ruddington, Nottingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.